This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ANX-510, 5,10-methylenetetrahydrofolate (mTHF), CH2FH4, folitixorin calcium
Description: CoFactor is a folate. Folates have been associated with increased levels of the compound MTHF (methylenetetrahydrofolate), which inhibits activity of the enzyme TS (thymidylate synthase). TS is essential to cell division, tissue regeneration, and tumor growth.
CoFactor is designed to improve the effectiveness of the anti-cancer drug 5-FU. It binds to the active metabolite (FdUMP) of 5-FU to create irreversible inhibition. CoFactor stimulates DNA synthesis so that 5-FU is taken up by cancer cells, enabling the irreversible inhibition, which results in cancer cell death and successful treatment with 5-FU.
Deal Structure: In June 2010, ADVENTRX Pharmaceuticals announced that it has granted Theragence exclusive, worldwide rights under its know-how to develop, make, use and sell CoFactor. Under the terms of their agreement, Theragence will use commercially reasonably efforts to research, develop and commercialize licensed products. ADVENTRX will receive royalties on net sales of licensed products and up to approximately $30 million in commercial milestones based on aggregate gross sales of licensed products in the United States, European Union and Japan.
Partners: Mast Therapeutics, Inc.
Pink Sheet FDA Performance Tracker: CDER Approvals
Additional information available to subscribers only: